Bedrijfsoverzicht
Mangoceuticals, Inc. is a specialized entity within the healthcare sector, specifically operating in the health information services industry, where it focuses on the development, marketing, and sale of men's wellness products and services through a dedicated telemedicine platform in the United States. The company's product portfolio includes erectile dysfunction solutions under the Mango brand, hair loss treatments under the Grow brand, and hormone balance offerings, all delivered via a digital healthcare interface. As of the latest available data, the company operates with a market capitalization of $5.77 million and employs a small workforce of three individuals, generating annual revenue of $456,021. These valuation and revenue figures indicate that Mangoceuticals is a micro-cap enterprise with a significantly limited operational scale, suggesting that its business model relies heavily on high-margin digital distribution rather than traditional pharmaceutical manufacturing or extensive sales infrastructure.
Financiële gezondheid
The financial performance of Mangoceuticals, Inc. over the trailing twelve months reveals a revenue stream of $456,021, which stands in stark contrast to a net income of -$21,818,994, highlighting a severe disconnect between top-line growth and profitability. The company also reports an EBITDA of -$15,869,579, indicating substantial operating losses that are not fully offset by non-cash adjustments like depreciation, pointing to a cost structure where fixed expenses or one-time charges likely outweigh operational cash generation. Despite these significant accounting losses, the company maintains a positive free cash flow of $1.88 million, suggesting that the business generates sufficient cash from operations to cover capital expenditures and working capital requirements without needing external equity financing at this stage. This positive cash flow provides a degree of financial flexibility that allows the company to continue its development and marketing initiatives despite the negative net income reported on an accrual basis. The company's profitability metrics further illustrate this disparity, with a gross margin of 54.9% showing efficient production or sourcing, yet an operating margin of -1576.4% and a profit margin of 0.0% reflecting extreme operational inefficiencies or significant non-operating expenses impacting the bottom line. On the liquidity side, Mangoceuticals holds $1.49 million in cash against total debt of $307,823, resulting in a debt-to-equity ratio of 2.02 which, while indicating leverage, is supported by a current ratio of 1.74 that suggests adequate short-term liquidity to meet obligations due within the next year. However, the return on equity stands at -141.7% and the return on assets is -69.9%, metrics that reveal that management has struggled to generate returns on the capital invested in the business, potentially due to the aggressive nature of its expansion or the early-stage status of its telemedicine platform.
Waarderingsbeoordeling
Valuation multiples for Mangoceuticals, Inc. present a complex picture due to its lack of profitability, as evidenced by a trailing P/E ratio and a forward P/E ratio both listed as N/A, which implies that traditional earnings-based valuation models cannot be applied given the company's significant net losses. The absence of a positive earnings trajectory means that the market is not pricing in immediate earnings recovery, leading to a reliance on alternative metrics such as the price-to-book ratio of 0.30, which indicates the stock is trading well below its book value and suggests a significant market discount or a high risk of insolvency if losses persist. The price-to-sales ratio of 12.65 and an EV/EBITDA of -0.29 further emphasize that investors are valuing the company based on its revenue potential and asset base rather than current earnings power, a common characteristic for pre-profitability biotech or healthcare tech firms. In terms of price action, the stock has a 52-week high of $2.88 and a 52-week low of $0.16, meaning the current share price sits significantly closer to the bottom of this trading range, reflecting the market's caution regarding its financial stability. The company exhibits a beta of 2.55, a figure that indicates its stock price is highly volatile and tends to fluctuate with much greater intensity than the broader market, exposing shareholders to substantial short-term price swings that are independent of the company's fundamental earnings performance.
Growth & Income
Mangoceuticals, Inc. experienced a revenue decline of -10.3% year-over-year, while earnings growth is listed as N/A due to the company's continued losses, indicating that the company is currently in a phase where revenue contraction is occurring alongside deep profitability challenges. Since the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, which signifies that the firm is retaining all of its limited earnings and cash flows to fund operations and potentially future growth initiatives rather than returning capital to shareholders. The combination of negative revenue growth and a lack of dividend income paints a profile of a company prioritizing survival and platform development over shareholder yield or consistent profitability in the current fiscal period. Consequently, the overall growth and income profile of Mangoceuticals, Inc. is characterized by a contraction in top-line revenue and a complete absence of dividend distributions, reflecting the high-risk, high-volatility nature of its business model within the competitive men's wellness sector.